The expanding role of antiplatelet agents in coronary artery disease: A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines

Minerva Cardioangiologica

Volumn 51, Issue 5, 2003, Pages 531-546

  Hostefter, J C ^a   Bhatt, D L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Coronary disease; Platelet aggregation inhibitors; Platelet glycoprotein IIb IIIa complex

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CD40 LIGAND; CLOPIDOGREL; CYCLIC GMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; IBUPROFEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; ORBOFIBAN; PARACETAMOL; PRAVASTATIN; PROSTAGLANDIN A2; PYRIDINE DERIVATIVE; ROFECOXIB; SIBRAFIBAN; SIMVASTATIN; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; XEMILOFIBAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HEART PROTECTION; HUMAN; NEUTROPENIA; OUTCOMES RESEARCH; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ASPIRIN; CORONARY ARTERIOSCLEROSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES;

EID: 0348050060     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks B et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
2. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002;88:711-5.
3. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000;102:840-5.
4. Patrano C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72: 1177-84.
5. Autry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-18.
6. Lopez-Farre A, Caramello C, Esteban A, Alberola ML, Millas I, Monton M et al. Effects of aspirin on platelet-neutrophil interactions: role of nitric oxide and endothelin-1. Circulation 1995;91:2080-8.
7. Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low-density lipoprotein from oxidative modification. Heart 1997;77:333-7.
8. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial function in atherosclerosis. Circulation 1998;97:716-20.
9. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309: 396-403.
10. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985;313:1369-75.
11. ISIS-2 (2nd International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither, among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
12. Wallentin LC and the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991;18: 1587-93.
13. Braunwald E, Antman E, Beasley J, Califf RM, Cheitlin MD, Hochman JS et al. ACC/AHA 2002 Guideline Update for the Management of Patients with Unstable Angina and non-ST-Segment Elevation Myocardial Infarction - Summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 2002;40:1366-74.
14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;208:81-106.
15. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
16. Goldstein RE, Andrews M, Hall W, Moss AJ for the Multicenter Myocardial Ischemia Research Group. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol 1996;28:326-30.
17. Steering Committee of the Physicians Heath Study Research Group. Final report on the aspirin component of the ongoing Physicians Heath Study. N Engl J Med 1989;321:129-35.
18. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233-41.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertensive Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
20. Collaborative Groupo of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001;357:89-95.
21. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K et al. Randomized trial of prophylactic aspirin in British male doctors. BMJ 1988;296:313-6.
22. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998;280:1930-5.
23. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmac 1993;35:219-26.
24. Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long-term aspirin: meta-analysis. BMJ 2000;321: 1183-7.
25. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
26. Lauer MS. Aspirin for the primary prevention of coronary events. N Engl J Med 2002;346:1468-74.
27. US Preventative Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 2002;136: 157-60.
28. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002;106:388-91.
29. Cairns JA, Theroux P, Lewis HD, Ezekowitz M, Meacle TW. Antithrombotic agents in coronary artery disease. Chest 2001;119:228S-52S.
30. Mehta J, Mehta P, Burger C, Pepine CJ. Platelet aggregation studies in coronary artery disease. Effect of aspirin. Atherosclerosis 1978;31:169-75.
31. Buchanan MR, Brister SJ. Individual variation in effects of aspirin on platelet function: implications for the use of aspirin clinically. Can J Cardiol 1995; 11:221-7.
32. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991;587-93.
33. Mueller MR, Salat A, Strangl P, Murabito M, Pulaki, S Boehm D et al. Variable platelet response to low-dose aspirin and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 997;78:1003-7.
34. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-76.
35. Eikelboom JW, Hirsch J, Weitz JI, Jonston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
36. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 1999;83:1147-51.
37. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.
38. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin: could it be thromboxane A2? Circulation 2002;105: 1620-2.
39. Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
40. Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl(A) polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997;96:1424:31.
41. Sperr WR, Huber K, Roden M, Janisiw M, Lang T, Graf S et al. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 1998;90:117-23.
42. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet 1998;35:1253.
43. Feng D, Lindpainter K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I et al. Increased platelet aggregability associated with platelet glycoprotein IIIa PlA2 polymorphism. Arterioscler Thromb Vasc Biol 1999;19:1142-7.
44. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpainter K. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997;349:385-8.
45. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L et al. Platelet glycoprotein IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000;101:1013-8.
46. Kastrati A, Schomig A, Seyforth M, Koch W, Elezi S, Bottiger L. Pl(A) polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005-10.
47. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4.
48. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiaro AJ, Demarco S, Tournier B. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
49. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
50. Livio M, Dehnaschio A, Cerletti C, deGaetano, G. Indomethacin prevents long-lasting inhibitory effects of aspirin on human platelet cyclooxygenase. Prostaglandins 1982;23:787-96.
51. Rao GHR, Jonson GG, Reddy KR, While JG. Ibuprofen protects platelet cyclooxygenase from irreversible acetylation by aspirin. Arteriosclerosis 1983;3:383-8.
52. Bombardier C, Loren L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-8.
53. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
54. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen,diclofenac, and nabumetone). Am J Cardiol 2002;89:204-9.
55. White WB, Faich G, Whelton A, Clemenet M, Ridge NJ, Verburg KM et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-30.
56. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6.
57. Whelton A, White WB, Bello AE, Puma JA, Fort JG and the SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients greater than 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
58. Fitzgerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003;361:542-3.
59. Kleiman NS, Lincoff, AM, Ohman EM, Harrington RA. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundations and clinical findings. Am Heart J 1998;136:532-42.
60. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angiography. N Engl J Med 1994;330:956-61.
61. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
62. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
63. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
64. The IMPACT II Investigators. Randomized placebo-controlled trial on effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-8.
65. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
66. The ESPRIT Investigators. Novel dosing of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356: 2037-44.
67. Bhatt DL, Marso SP, Lincoff AM, Wolski K, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.
68. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-9.
69. Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation 2000;102:28-34.
70. Karvouni E, Katritsis DG, Ioannidis JPA. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary intervention. J Am Coll Cardiol 2003;41:26-32.
71. Roe MJ, Gum PA, Booth JE. Consistent and durable reduction in death and myocardial infarction with abciximab during reduction during coronary intervention in acute coronary syndromes and unstabte angina. Circulation 1999;100:I-187.
72. Brener SJ, Barre LA, Burchenal JEB, Katz S, George BB, Jones AA et al. Randomized, placebo-controlled triat of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-41.
73. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P et al. for the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
74. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ et al. for the CADILLAC Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
75. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000;284:1549-58.
76. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002;359:189-98.
77. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in acute coronary syndromes. Eur Heart J 2002;23:1441-8.
78. Marso SP, Bhatt DL, Roe MT, Houghtaling PL, Labinaz M, Kleiman NS et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation 2000;102:2952-8.
79. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 2001;104:2767-71.
80. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Eur Heart J 2002;23:223-9.
81. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet 2001;357:1915-24.
82. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
83. Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C. Outcomes at six months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement. The TARGET follow-up study. Lancet 2002;360:355-60.
84. Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo, L, White MM, Longhurst C et al. Effect of Ca2+ on glycoprotein IIb/IIIa interactions with integrillin: enhanced glycoprotein IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentrations of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-94.
85. Chew DP, Bhatt DL. Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials. Intern Med J 2002;32:338-45.
86. Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell M, Dillard P et al. Randomized comparison of platelet inhibition with abciximab, tirofiban, and eptifibatide during percutaneous coronary intervention in acute coronary syndromes. The COMPARE trial. Circulation 2002;106:1470-6.
87. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N et al. for the TACTICS-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
88. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
89. Chew DP, Bhatt, DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists. Circulation 2001;103:201-6.
90. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev 2003;2:15-28.
91. Steinhubl SR, Talley D, Braden GA, Tcheng JE, Casterella PG, Moliterno DJ. Point of care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Circulation 2001;103:2572-8.
92. Heeschen C, Dimmeler S, Hamm CW, Van den Brand MJ, Boersma E, Zeiher AM et al. for the CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11.
93. Schonbeck U, Varo, N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-8.
94. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003;1078:1123-8.
95. Blankenship JC. Bleeding complications of glycoprotein IIb/IIIa receptor inhibitors. Am Heart J 1999;138: S287-S96.
96. Sabatine MS, Jang IK. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 2000;109:224-37
97. Memon MA, Blankenship JL, Wood GC, Frey CM, Menapace FJ. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med 2000;109:213-7.
98. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140:206-11.
99. The CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at high risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
100. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-72.
101. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001;86:222-37.
102. Lubbe DF, Berger PB. The thienopyridines. J Interv Cardiol 2002;15:85-93.
103. Scrutinio D, Lagioia R, Rizzon P on behalf of the Studio della Ticlopidina nell'Angina Instabile Group. Ticlopidine treatment for patients with unstable angina at rest. Eur Heart J 1991;12:27-9.
104. Balsan F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990;82:17-26.
105. Gent M, Easton JD, Hachinski UC, Panak E, Sicurella J, Blakely JA. The Canadian American Ticlopidine Study (CATS) in Thromboembolic stroke. Lancet 1989;1:1215-20.
106. Has WK, Easton JD, Adams HP, Pryse-Phillips W, Malony BA, Sharon A et al. for the Ticlopidine Aspirin Stroke Study (TASS) Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-7.
107. Becquemin JP for the Etude de la Ticlopidine après Pontage Femor-Poplite and the Association Universitaire de Recherche en Chirurgie. Effect of ticlopidine on the long-term patency of saphenousvein bypass grafts in the legs. N Engl J Med 1997;337:1726-31.
108. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
109. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KL et al. for the Stent Anticoagulation Restenosis Study (STARS) Investigators. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med 1998;339:1665-71.
110. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. A full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-603.
111. Steinhubl SR, Tan WA, Foody JM, Topol EJ for the EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999;281:806-10.
112. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-8.
113. Bhatt, DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-8.
114. Berger PB, Bell MR, Rihal CS, Ling H, Barsness G, Garratt K. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34: 1891-4.
115. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared to ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102: 624-9.
116. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.
117. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
118. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BJ, Natarajan MK et al. Effect of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention. The PCI-CURE study. Lancet 2001;358:527-33.
119. Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2000;102:1093-100.
120. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7.
121. Steinbuhl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer C et al. for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002;288:2411-20.
122. Kastrati A. Abciximab not needed in elective PCI if high loading dose of clopidogrel used. Heartwire Mar. 30, 2003.
123. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003;107:32-7.
124. Serebruany VL, Malinin AI, Callahan KP, Steinhubl SR. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 2001;159:239-41.
125. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP et al. The effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with c-reactive protein. Am J Cardiol 2001;88:672-4.